Bumetanide as a Model NDSRI Substrate: N-nitrosobumetanide Impurity Formation and its Inhibition in Bumetanide Tablets

• Published in: Journal of pharmaceutical sciences 2023-12, Vol.112 (12), p.3075-3087
• Main Authors: Shakleya, Diaa, Asmelash, Bethel, Alayoubi, Alaadin, Abrigo, Nicolas, Mohammad, Adil, Wang, Jiang, Zhang, Jinhui, Yang, Jingyue, Marzan, Tim Andres, Li, David, Shaklah, Maha, Alsharif, Fahd M., Desai, Saaniya, Faustino, Patrick J., Ashraf, Muhammad, O'Connor, Thomas, Vera, Matthew, Raw, Andre, Sayeed, Vilayat A., Keire, David
• Format: Article
• Language: English
• Subjects: Ascorbic acid; Bumetanide; Caffeic acid; Ferulic acid; Mitigation; N-nitrosobumetanide; Nitrite; Stability
• ISSN: 0022-3549; 1520-6017
• DOI: 10.1016/j.xphs.2023.06.013

Nitrosamine compounds are classified as potential human carcinogens, the origin of these impurities can be broadly classified in two categories, nitrosamine impurity found in drug products that are not associated with the Active Pharmaceutical Ingredient (API), such as N-nitrosodimethylamine (NDMA) or nitrosamine impurities associated with the API, such as nitrosamine drug substance-related impurities (NDSRIs). The mechanistic pathway for the formation of these two classes of impurities can be different and the approach to mitigate the risk should be tailored to address the specific concern. In the last couple of years number of NDSRIs have been reported for different drug products. Though, not the only contributing factor for the formation of NDSIRs, it is widely accepted that the presence of residual a nitrites/nitrates in the components used in the manufacturing of the drug products can be the primary contributor to the formation of NDSRIs. Approaches to mitigate the formation of NDSRIs in drug products include the use of antioxidants or pH modifiers in the formulation. The primary objective of this work was to evaluate the role of different inhibitors (antioxidants) and pH modifiers in tablet formulations prepared in-house using bumetanide (BMT) as a model drug to mitigate the formation of N-nitrosobumetanide (NBMT). A multi-factor study design was created, and several bumetanide formulations were prepared by wet granulation with and without sodium nitrite spike (100 ppm) and different antioxidants (ascorbic acid, ferulic acid or caffeic acid) at three concentrations (0.1%, 0.5% or 1% of the total tablet weight). Formulations with acidic and basic pH were also prepared using 0.1 N hydrochloric acid and 0.1 N sodium bicarbonate, respectively. The formulations were subjected to different storage (temperature and humidity) conditions over 6 months and stability data was collected. The rank order of N-nitrosobumetanide inhibition was highest with alkaline pH formulations, followed by formulations with ascorbic acid, caffeic acid or ferulic acid present. In summary, we hypothesize that maintaining a basic pH or the addition of an antioxidant in the drug product can mitigate the conversion of nitrite to nitrosating agent and thus reduce the formation of bumetanide nitrosamines.